Email this article 
Hide
Show all
Clinical Perspective
Nephrogenic systemic fibrosis (NSF) and gadolinium-based contrast media
South African Journal of Radiology | Vol 17, No 3 | a277 |
DOI: https://doi.org/10.4102/sajr.v17i3.277
| © 2013 P.S. Ngoya, Z Vawda, J.W Lotz
| This work is licensed under CC Attribution 4.0
Submitted: 24 February 2013 | Published: 01 August 2013
Submitted: 24 February 2013 | Published: 01 August 2013
About the author(s)
P.S. Ngoya, Radiodiagnosis Division, University of Stellenbosch and Tygerberg Academic Hospital, Parow, Western Cape, South AfricaZ Vawda, Radiodiagnosis Division, University of Stellenbosch and Tygerberg Academic Hospital, Parow, Western Cape, South Africa
J.W Lotz, Radiodiagnosis Division, University of Stellenbosch and Tygerberg Academic Hospital, Parow, Western Cape, South Africa
Abstract
Nephrogenic systemic fibrosis (NSF), unknown before March 1997 and first described in 2000, is a systemic disorder characterised by widespread tissue fibrosis. The first known case occurred in 1997, after the use of gadolinium-based contrast agents (GBCAs) at high doses in patients with renal failure had become routine. An overwhelming majority occurred within weeks to months after injection of a GBCA. This note comprises guidelines on the prevention of NSF.
Keywords
Nephrogenic systemic fibrosis; NSF; gadolinium-based contrast agents; GBCA; gadolinium-based contrast media
Metrics
Total abstract views: 4316Total article views: 4648